Quantcast

Industry news that matters to you.  Learn more

Archives for June 2012

Plexpress Oy and Phalanx Biotech Group Offer Biomarker Discovery and Validation Service

Plexpress Oy, the creator of the innovative TRAC platform for high-throughput gene expression analysis, and Phalanx Biotech Group, the original design manufacturer of the OneArray line of high-quality microarrays for gene expression and microRNA profiling, have established a strategic alliance to offer the OneTRAC service. The new service package will allow researchers to not only discover and select genomic biomarkers, but also to fully validate and understand their function in a streamlined, integrated workflow. The OneTRAC analysis service will be offered by Plexpress in Europe, and by Phalanx Biotech in the United States and Asia.

The Michael J. Fox Foundation Extends Funding for KineMed’s Brain-Process Biomarker Research for Parkinson’s Disease

KineMed, Inc. announced today a further award of $1.2 Million from The Michael J. Fox Foundation towards the ongoing development of kinetic biomarkers that drug developers can use to accelerate and reduce the cost of trials of treatments for Parkinson’s disease (PD).

ALPCO and Argutus Medical Collaboration

ALPCO Diagnostics, a leading developer, manufacturer and distributor of assays, is pleased to announce the launch of their new site specific rat kidney injury biomarker, Alpha Glutathione-S-Transferase (aGST) a constitutive proximal tubule injury marker. The biomarker has been widely referenced in scientific publications as well as studied by the ILSI HESI Committee on the Application of Biomarkers of Toxicity, Nephrotoxicity Working Group. Results of this collaborative study have been submitted to various U.S., EU and Japanese regulatory as part of the FDA CDER biomarker qualification initiative.

Caris Life Sciences Launches Caris Target Now Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary

Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now™ Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the original Caris Target Now comprehensive molecular profiling service offering for all solid tumors.

Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.

Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. (NASDAQ: CGEN) today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Further financial details of the agreement were not disclosed.